Consultant, Medical Oncology, Fortis Flt. Lt. Rajan Dhall Hospital, Vasant Kunj, New Delhi
Part 4 of 13 in From Detection to Recovery: Navigating the Future of Cancer Care
Why Biopsy Beats FNAC in Cancer Diagnosis
September 6, 2026
FNAC was once the standard first step in confirming a suspected cancer. Dr. Nithin S.G. now considers it largely obsolete, and explains why core and excisional biopsy have taken its place for almost every cancer type.
The Problem With FNAC
Fine needle aspiration cytology involves inserting a needle into a lump or fluid-filled cyst and drawing off fluid along with a small number of detached cells. Because so few cells come through, a pathologist examining the slide can usually only confirm that abnormal cells are present, not identify the exact cancer subtype. That distinction matters more today than it did fifteen or twenty years ago: modern breast cancer treatment, for instance, depends on knowing hormone receptor and HER2 status, tests that need far more tissue than FNAC can provide. FNAC can also rupture the tumour capsule during sampling and risk spreading the cancer.
Core Biopsy and Excisional Biopsy
A core biopsy uses a biopsy gun to remove a cylindrical piece of tissue roughly a centimetre long, enough for histopathology, hormone receptor testing and the genetic sequencing that now guides targeted therapy. A lump in the breast or a swelling outside the body can be biopsied directly; a mass in the abdomen or lung is biopsied under ultrasound or CT guidance, and upper gastrointestinal cancers are biopsied by endoscopy, colon and rectal cancers by colonoscopy. For a suspicious lymph node, an excisional biopsy, removing the entire node rather than a core sample, is preferred wherever the node is accessible, since lymphoma specifically cannot always be diagnosed if the node's capsule is broken during sampling; a core or CT-guided biopsy is used instead only when the node itself is not surgically accessible, such as in the abdomen or lungs.
Cancers Where No Biopsy Is Done At All
A small group of cancers are deliberately not biopsied, because biopsy itself risks rupturing the capsule and spreading disease. A kidney mass on CT or ultrasound goes straight to surgery rather than a confirmatory biopsy. Testicular swellings are managed the same way, straight to orchiectomy, since biopsy of a capsulated organ like the testis carries the same rupture risk. A confirmed liver mass in a cirrhotic patient, supported by a triple-phase CT and an elevated AFP, does not need tissue confirmation either, and retinoblastoma in children is diagnosed on eye examination alone.
← From Suspicion to Diagnosis: Blood Tests and Imaging Explained | Series index | Tumour Markers: What They Can and Cannot Tell You →
This article is based on a Jivo Masterclass session conducted by Dr. Nithin S.G., Consultant, Medical Oncology, Fortis Flt. Lt. Rajan Dhall Hospital, Vasant Kunj, New Delhi. The article has been summarised with the assistance of an AI tool from the original masterclass recording. Watch the full Masterclass recording
This guide is based on a live Jivo Masterclass: Dr. Nithin S.G. taught doctors across Africa on May 11, 2025.
FROM THE LIVE Q&A
Yaram
What specific investigation should be used to diagnose testicular cancer?
Dr. Nithin S.G.
Any scrotal swelling should first be evaluated with ultrasound, which will show a testicular mass or enlargement, but there is no test that gives a confirmed diagnosis before surgery, that only comes after radical orchiectomy. Of 100 patients presenting with a testicular swelling, roughly 80 to 90 percent will have cancer and about 10 percent tuberculosis, so for the large majority a biopsy is avoided, since it risks spreading the cancer, in favour of going directly to orchiectomy. Tumour markers such as AFP and beta-hCG, elevated in seminoma and yolk-sac tumours, can support the ultrasound finding, but the standard recommendation regardless of marker levels is orchiectomy rather than biopsy.
Frequently Asked Questions
How specific is PSA for prostate cancer, given a case where PSA was over 100 but the biopsy showed only BPH?▼
PSA is not specific for prostate cancer at all, no tumour marker is specific for any single cancer. An elevated PSA in a patient with a prostatic mass could reflect BPH or cancer, and can rise even after a digital rectal exam or ejaculation. Very high values, such as over 100, are more suggestive of cancer, so if PSA is extremely elevated yet the biopsy shows only BPH, the biopsy may simply have missed the cancerous core, which does happen. In such suspicious cases, a gallium-68 PSMA PET scan, highly specific for prostate cancer, can help confirm or rule out malignancy before treating for BPH alone.
Should breast cancer be diagnosed with a core biopsy or an excisional biopsy?▼
Core needle biopsy is sufficient for breast cancer, and there is no need for excisional biopsy in most cases. For a small tumour such as a fibroadenoma, excisional biopsy is an option, but core needle biopsy is equally effective, and if the mass proves benign, surgery can be avoided altogether.
Can precision oncology or targeted therapy offer a drug for uterine fibroids, since they are so common?▼
Unfortunately there is no specific genetic mutation identified for uterine fibroids and no targeted drug role for them, since fibroids are benign tumours, not cancers. Treatment options remain limited to hormonal therapy or surgery.
What is your opinion on targeted therapy for advanced cancer patients with a poor performance status?▼
Targeted therapy's main advantage is that it is mostly oral medication without the classic side effects of chemotherapy, so it remains a reasonable option even in poor performance status, though this depends on the specific drug and its side-effect profile rather than being a blanket rule. Two cases illustrate this: a metastatic lung cancer patient with brain metastases who was bedridden with severe headache and vomiting, and a metastatic breast cancer patient with cerebellar metastasis causing incoordination, both showed marked improvement on targeted therapy despite their poor baseline state. Overall, more patients in poor performance status can be treated with targeted therapy than with chemotherapy, since chemotherapy is often not feasible in a very poor clinical state.
What is the difference between FNAC, core biopsy and excisional biopsy?▼
FNAC (fine needle aspiration cytology) involves inserting a needle into a tumour or fluid-filled cyst and aspirating fluid along with a few detached cells for slide evaluation under a microscope; sensitivity is low since so few cells come through, and a pathologist can typically only confirm abnormal cells are present, not the exact cancer subtype needed for hormone receptor and HER2 testing. Core biopsy uses a biopsy gun that removes a cylindrical piece of tissue roughly a centimetre long, providing enough tissue for full histopathological and genetic workup, which is why core biopsy, not FNAC, is preferred whenever cancer is suspected.
Why is FNAC no longer the preferred way to diagnose cancer?▼
FNAC yields too few cells for a pathologist to identify the exact cancer subtype or run hormone receptor and genetic tests, and it can rupture the tumour capsule during sampling.
Why is an excisional biopsy preferred for a suspicious lymph node?▼
Because lymphoma specifically cannot always be diagnosed if the node's capsule is broken during sampling, so the whole node is removed intact wherever it is surgically accessible.
Which cancers are diagnosed without any biopsy at all?▼
A kidney mass, a testicular swelling, a cirrhotic liver mass with elevated AFP, and retinoblastoma in children are all managed without a diagnostic biopsy, since biopsy itself risks spreading the disease in these cases.
In This Series: From Detection to Recovery: Navigating the Future of Cancer Care
- 1.From Detection to Recovery
- 2.When to Suspect Cancer: A Symptom Checklist by Cancer Type
- 3.From Suspicion to Diagnosis: Blood Tests and Imaging Explained
- 4.Why Biopsy Beats FNAC in Cancer Diagnosis
- 5.Tumour Markers: What They Can and Cannot Tell You
- 6.Cancer Staging and Why It Decides the Treatment Plan
- 7.Precision Oncology: How Genetic Testing Is Changing Cancer Treatment
- 8.Immunotherapy: Retraining the Immune System to Fight Cancer
- 9.Breast Cancer: Subtypes, Diagnosis and Newer Targeted Treatments
- 10.Targeted Therapy for Advanced Cancer Patients with Poor Performance Status
- 11.Testicular Cancer, Prostate Cancer and PSA: Working Up Common Urologic Presentations
- 12.Liquid Biopsy: A Newer, Less Invasive Way to Detect and Monitor Cancer
- 13.Uterine Fibroids Are Not Cancer: Why Targeted Therapy Doesn't Apply